FDA Approves Novo Nordisk's Sogroya® for Turner Syndrome in Children

11/20/2026
Impact: 65
Healthcare

The FDA approved Novo Nordisk’s once-weekly growth hormone Sogroya (somapacitan-beco) for children aged 2.5 years and older with growth failure associated with Turner Syndrome. The decision was supported by efficacy and safety results from the pivotal REAL8 trial. Sogroya is now indicated for growth hormone deficiency and four other growth-related conditions, including Idiopathic Short Stature, Noonan Syndrome, and short stature in children born Small for Gestational Age.

AI summary, not financial advice

Share: